search
Back to results

Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression

Primary Purpose

Symptomatic Irreversible Pulpitis

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Prednisolone 30 mg
Diclofenac Potassium 50mg Tab
Placebo
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Symptomatic Irreversible Pulpitis focused on measuring prednisolone, diclofenac potassium, interleukin-8

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age between 18-50 years.
  • Males and females.
  • American Society of Anesthesiologists class 1 or 2.
  • Mandibular premolar teeth with:

    • Endodontic pulpal diagnosis of symptomatic irreversible pulpitis
    • Normal/slight widening in the periodontal membrane space (PMS).
  • Patients who had not taken any anti-inflammatory drugs the day of the root canal procedure unless they belong to one of the intervention groups.
  • Patients who accept to participate in the trial, understand the VAS, and can sign the informed consent

Exclusion Criteria:

  • Cases with acute peri-apical conditions (acute apical periodontitis/ acute apical abscess), pulpal necrosis, previously initiated therapy, or previously treated.
  • Teeth other than single-rooted teeth.
  • Radiographic evidence of external or internal root resorption vertical root fracture, perforation, or calcification.
  • Immature teeth.
  • Unrestorable teeth or teeth with severe periodontal disease.
  • Patients with a known allergy, sensitivity, or history of other adverse reactions to the medications administered.
  • Patients with a history of active peptic ulcer within the preceding 12 months, bleeding problems, anticoagulant use within the last month, or kidney disease.
  • Patients who took analgesics/ anti-inflammatory drugs (steroidal or non-steroidal) the day of endodontic treatment.
  • Pregnant or nursing females.
  • Patients who are unable to provide informed consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    Prednisolone premedication

    Diclofenac potassium premedication

    Placebo

    Arm Description

    Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.

    Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.

    Placebo tablet 1 hour before starting endodontic treatment.

    Outcomes

    Primary Outcome Measures

    Change in the intensity of post-endodontic pain
    Pain intensity will be evaluated using visual analogue scale

    Secondary Outcome Measures

    Quantification of pulpal IL-8
    Il-8 analasys will be done via enzyme-linked immunosorbent assay (ELISA)

    Full Information

    First Posted
    October 13, 2020
    Last Updated
    October 25, 2020
    Sponsor
    Cairo University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04608981
    Brief Title
    Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression
    Official Title
    Effect of Diclofenac Potassium Versus Prednisolone as a Premedication on Post-endodontic Pain and Pulpal Interleukin (IL)-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2021 (Anticipated)
    Primary Completion Date
    December 2021 (Anticipated)
    Study Completion Date
    February 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Cairo University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To assess the effect of using diclofenac potassium versus prednisolone as a pre-medication compared to placebo on: Intensity of post-endodontic pain in patients with symptomatic irreversible pulpitis. Pulpal IL-8 expression. Incidence of post-endodontic pain in patients with symptomatic irreversible pulpitis.
    Detailed Description
    After confirming the diagnosis and making sure that the patient conforms to all eligibility criteria, the principal investigator will enroll the patient in the study. Patients will be asked to rate their pre-operative pain intensity (ie, before the commencement of any treatment [baseline score]; on the visual analogue scale "VAS" Enrolled patients will be randomly assigned into one of three groups: Intervention Group 1 (Diclofenac Potassium): single, oral dose of 50 mg diclofenac potassium pre-medication (Cataflam; NOVARTIS Pharma, Basel, Switzerland) one hour before starting endodontic treatment. Intervention Group 2 (Prednisolone): single, oral dose of 30 mg prednisolone (one and a half tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France) 30 min before starting endodontic treatment. Control Group (Placebo): The patients assigned to this group will be given a placebo tablet (Starch, Bridgewater, NJ) one hour before starting endodontic treatment. - Root canal therapy in all groups will be completed by the principal investigator in a single visit as follows: Anesthetizing the tooth using inferior alveolar nerve block technique by local anesthesia of 1.8 ml of 2% Mepivacaine HCl with 1:100,000 epinephrine. After anesthesia is achieved and verified with Endo-Ice, the patient's tooth is isolated with a rubber dam, caries is excavated, and the pulp is exposed with a sterile round bur. Preparation of access cavity using a sterile round carbide bur and an Endo-Z bur Sample Collection: Blood from the exposed surface of the pulp will be collected with 2 sterile cotton pellets. The pellets will be held at the exposure site for 45-60 seconds to allow absorption of the blood from the pulpal tissue. The pellets will be placed in 1.0 mL saline in heparin-coated tubes. Samples will be placed on ice and stored/refrigerated immediately at -20 degrees celsius until they are ready to be tested. After the pulpal blood sample is collected, patency of the root canals will be confirmed using stainless steel hand K-files sizes #10 and #15. Working length will be determined using an electronic apex locator then confirmed radiographically to be 1 mm shorter than radiographic apex. Mechanical preparation will be completed in a crown down technique with ProTaper Next10 rotary files set on an endodontic motor adjusted at a speed of 300 rpm and torque of 200 gcm. In-and-out motions will be applied with stroke lengths not exceeding 3mm in the cervical, middle, and apical thirds until attaining the established WL. The root canal will be thoroughly irrigated with 3 mL of 2.6% sodium hypochlorite using a plastic disposable syringe with a 30-gauge side-vented needle reaching 1mm short of the working length between every subsequent instrument, whereas saline will be used as the final irrigant. The canal will then be dried using sterile paper points. Master cone fit radiograph will be taken and then the root canal will be obturated at the same appointment with matching-size gutta percha points and resin-based sealer using cold lateral compaction technique. Access cavity will be sealed with Coltosol F temporary filling material. At the end of the session, each patient will be instructed to complete a pain diary, (VAS), at specific intervals; immediately after treatment completion; and 6, 12, 24, and 48 hours after the completion of treatment. The patient will be asked to mark the level of pain on this 10-cm line. The distance from the left end to the mark made by the patient, which will be measured by the operator with a ruler, is the pain intensity. Patients will be contacted by their operator at each time-point to check on them and as a reminder. Then, information will be documented.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Symptomatic Irreversible Pulpitis
    Keywords
    prednisolone, diclofenac potassium, interleukin-8

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Masking Description
    In this proposed study, the participant, and the assessor will be blinded. The participants will be blinded to the study hypothesis as to which intervention is expected to be better. The patients, who already do not know their treatment group, will assess the level of their post-endodontic pain. The laboratory technician at the microbiological department will not know the treatment group of the patients. The treatment groups will remain anonymous at the end of the study during assessment by the statistician.
    Allocation
    Randomized
    Enrollment
    36 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Prednisolone premedication
    Arm Type
    Experimental
    Arm Description
    Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.
    Arm Title
    Diclofenac potassium premedication
    Arm Type
    Experimental
    Arm Description
    Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo tablet 1 hour before starting endodontic treatment.
    Intervention Type
    Drug
    Intervention Name(s)
    Prednisolone 30 mg
    Other Intervention Name(s)
    One and a half tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France
    Intervention Description
    Steroidal anti-inflammatory drug as a preoperative medication
    Intervention Type
    Drug
    Intervention Name(s)
    Diclofenac Potassium 50mg Tab
    Other Intervention Name(s)
    Cataflam; NOVARTIS Pharma, Basel, Switzerland
    Intervention Description
    Non-steroidal anti-inflammatory drug as a preoperative medication
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Starch
    Primary Outcome Measure Information:
    Title
    Change in the intensity of post-endodontic pain
    Description
    Pain intensity will be evaluated using visual analogue scale
    Time Frame
    Immediately after treatment completion; and at 6, 12, 24, and 48 hours post-operatively
    Secondary Outcome Measure Information:
    Title
    Quantification of pulpal IL-8
    Description
    Il-8 analasys will be done via enzyme-linked immunosorbent assay (ELISA)
    Time Frame
    During the procedure
    Other Pre-specified Outcome Measures:
    Title
    Change in the incidence of post-endodontic pain
    Description
    Pain incidence will be evaluated using visual analogue scale
    Time Frame
    Immediately after treatment completion; and at 6, 12, 24, and 48 hours post-operatively

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Age between 18-50 years. Males and females. American Society of Anesthesiologists class 1 or 2. Mandibular premolar teeth with: Endodontic pulpal diagnosis of symptomatic irreversible pulpitis Normal/slight widening in the periodontal membrane space (PMS). Patients who had not taken any anti-inflammatory drugs the day of the root canal procedure unless they belong to one of the intervention groups. Patients who accept to participate in the trial, understand the VAS, and can sign the informed consent Exclusion Criteria: Cases with acute peri-apical conditions (acute apical periodontitis/ acute apical abscess), pulpal necrosis, previously initiated therapy, or previously treated. Teeth other than single-rooted teeth. Radiographic evidence of external or internal root resorption vertical root fracture, perforation, or calcification. Immature teeth. Unrestorable teeth or teeth with severe periodontal disease. Patients with a known allergy, sensitivity, or history of other adverse reactions to the medications administered. Patients with a history of active peptic ulcer within the preceding 12 months, bleeding problems, anticoagulant use within the last month, or kidney disease. Patients who took analgesics/ anti-inflammatory drugs (steroidal or non-steroidal) the day of endodontic treatment. Pregnant or nursing females. Patients who are unable to provide informed consent
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ahmed A Soliman, MSc
    Phone
    +201006779533
    Email
    aasoliman89@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Sara S Abouelenien, PhD
    Phone
    +201000703203
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ahmed A Soliman, MSc
    Organizational Affiliation
    Cairo University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Khaled Ezzat, PhD
    Organizational Affiliation
    Cairo University
    Official's Role
    Study Director
    First Name & Middle Initial & Last Name & Degree
    Sara S Abouelenien, PhD
    Organizational Affiliation
    Cairo University
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression

    We'll reach out to this number within 24 hrs